An observational study in Atrial Fibrillation, sponsored by Hospital Álvaro Cunqueiro. Status unknown at 1 site in Spain. Per ClinicalTrials.gov, last updated 2020-04-28.
Sponsored by Hospital Álvaro Cunqueiro · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 247 studies in Atrial Fibrillation with a site in Spain — 53 open to participants now, 76 under way, 3 of them phase 3. Atrial Fibrillation · Spain.
Among the 247 studies in Atrial Fibrillation with a site in Spain, this one is the 4th largest by planned enrollment of the 85 observational ones that give a count, is one of 12 that started in 2018, is one of 85 observational ones, and was the 149th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →53 of the 247 studies in Atrial Fibrillation with a site in Spain are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain, Belgium, Germany and 3 more countries
Ages 18+
Hospital Universitario Getafe · Sites in Spain
Ages 18–80
Boston Scientific Corporation · Sites in Spain, United States, Belgium and 1 more country
Ages 18+
Boston Scientific Corporation · Sites in Spain, Belgium, Croatia and 2 more countries
Ages 18+
Abbott Medical Devices · Sites in Spain, Belgium, Czechia and 7 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
247 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 37 · Phase 4 27
First in 2001; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 304 across the 162 interventional studies, 500 across the 85 observational. Of the 154 that completed or were terminated, 60 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 247 have an industry lead sponsor. The 10 most frequent:
Hospital Álvaro Cunqueiro is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Hospital Álvaro Cunqueiro has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
24 of the studies in Atrial Fibrillation with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT07598903Centro de Emergencias Sanitarias 061 AndalucíaPharmacy-based Opportunistic Atrial Fibrillation Screening Integrated With Emergency Services (NUMAPLUS-FA) | 2026-12-15 |
| NCT07339007Societat Catalana de Medicina Familiar i Comunitària, Assoc. (CAMFiC)Observational Study to Validate a Family Physician Echocardiography Training Programme | 2026-12-31 |
| NCT07358611Hospital Clinic of BarcelonaNon-invasive Mapping-Guided Atrial Fibrillation Ablation | 2026-12-31 |
| NCT07390175Hospital San Carlos, MadridAblation of Human Cardiac Fibrillation Based on Models of Hierarchical Organization of Tissue Excitation | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 247 studies in Atrial Fibrillation with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Registry of all consecutive patients with atrial fibrillation from Heath Area of Vigo, since 2013 to 2020, in order to study therapy, mortality, cardiovascular complications and bleeding events.
Retrospective observational registry of patients diagnosed of atrial fibrillation between 2013 and 2020. Clinical, analytical and echocardiographic data will be recorded, as well as therapeutic prescription information. Data on mortality and cardioembolic and hemorrhagic events will be collected during follow-up. The aim is to study the prevalence and incidence of atrial fibrillation, the anticoagulant treatment according to cardioembolic risk, the thromboembolic events and hemorrhagic events, the risk of mortality (Cardiovascular, Non-Cardiovascular), the contemporary management (Rhythm control versus frequency control strategy), and other complications, such as heart failure, acute coronary syndrome or cancer.
All patients with atrial fibrillation from Health Area of Vigo
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
Also known as: Vitamin K Antagonists or Direct Oral Anticoagulants
Mortality
All cause Mortality
Time frame: Follow-up (3 years)
Bleeding
Bleeding according to International Society on Thrombosis and Haemostasis(ISTH) classiffication
Time frame: Follow-up (3 years)
Embolism
Embolic events include ischemic stroke, transient ischemic attack (TIA), pulmonary embolism (PE), and systemic embolism (SE). Ischemic stroke was defined as sudden onset of a focal deficit consistent with occlusion of a major cerebral artery (documented by means of magnet resonance imaging \[MRI \]or computer tomography \[CT\]) and categorized. TIA was defined as a temporary neurologic deficit presumably due to reduced blood flow in a particular cerebral artery lasting for ≤24 hours with complete resolution of the neurologic deficit. A PE event was confirmed by spiral CT, perfusion-ventilation scan, pulmonary angiography, or autopsy) and resulted in a final PE diagnosis. A SE event was defined as any end-organ ischemia other than in the brain, heart, eyes, and lungs, caused by abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of another likely mechanism.
Time frame: Follow-up (3 years)
Plan to share: Undecided — Data of CardioCHUVI-AF registry could be merge with other registries, always they have similar characteristics, with a same registry nature
Started Nov 2018 (actual). Primary completion is estimated for Nov 2022, 48 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.